We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celularity, Inc. (CELU) Stock Moves -0.11%: What You Should Know
Read MoreHide Full Article
Celularity, Inc. (CELU - Free Report) closed the most recent trading day at $0.64, moving -0.11% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.16%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, added 1.58%.
Prior to today's trading, shares of the company had lost 39.21% over the past month. This has lagged the Medical sector's loss of 2.26% and the S&P 500's gain of 0.84% in that time.
Wall Street will be looking for positivity from Celularity, Inc. as it approaches its next earnings report date. In that report, analysts expect Celularity, Inc. to post earnings of -$0.25 per share. This would mark a year-over-year decline of 733.33%. Our most recent consensus estimate is calling for quarterly revenue of $5.51 million, up 13.37% from the year-ago period.
Investors should also note any recent changes to analyst estimates for Celularity, Inc.These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 9.06% higher. Celularity, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Celularity, Inc. (CELU) Stock Moves -0.11%: What You Should Know
Celularity, Inc. (CELU - Free Report) closed the most recent trading day at $0.64, moving -0.11% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.16%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, added 1.58%.
Prior to today's trading, shares of the company had lost 39.21% over the past month. This has lagged the Medical sector's loss of 2.26% and the S&P 500's gain of 0.84% in that time.
Wall Street will be looking for positivity from Celularity, Inc. as it approaches its next earnings report date. In that report, analysts expect Celularity, Inc. to post earnings of -$0.25 per share. This would mark a year-over-year decline of 733.33%. Our most recent consensus estimate is calling for quarterly revenue of $5.51 million, up 13.37% from the year-ago period.
Investors should also note any recent changes to analyst estimates for Celularity, Inc.These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 9.06% higher. Celularity, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.